[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"St. Joseph's Healthcare Hamilton\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":672},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,29,0,25,[9,44,77,104,131,153,180,199,227,259,286,312,331,363,388,422,455,467,495,530,553,579,598,625,651],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100054287","an-innovative-master-platform-for-clinical-trials-in-mood-disorders-100054287",false,"NCT06408012","An Innovative Master Platform for Clinical Trials in Mood Disorders","Enabling Neuroscience Research Approaches for Brain, feeLings and Emotions (ENABLE): An Innovative Platform for Clinical Trials in Mood Disorders","ENABLE","Inclusion Criteria\n\nPatients:\n\n1. 16 years of age or older.\n2. Meet criteria for bipolar or depressive disorders as defined by DSM-5.\n3. Fluency in English, sufficient to complete the interviews and self-report questionnaires.\n\nInclusion Criteria\n\nHealthy Comparison (HC) Participants:\n\n1. 16 years of age or older.\n2. No history of psychiatric disorders (according to DSM-5) or significant unstable medical conditions.\n3. Fluency in English, sufficient to complete the interviews and self-report questionnaires.",true,"ALL","16 Years",{"count":22,"type":23},2200,"ESTIMATED","1 Day","OBSERVATIONAL","Mood disorders such as depression and bipolar disorder affect over 350 million people around the world. While several effective treatments exist, it is often difficult to match the right treatment to an individual person. Repeated efforts to find the right treatment contribute to poor functioning, low quality of life, and prolongs the time it takes to get well. Most areas of medicine are able to use 'biomarkers' or clinical tests, blood tests, or imaging to help diagnose and treat illness. The search for biomarkers in mood disorders is advancing, but one roadblock to progress is the lack of large, standardized studies of mood disorders that are needed to accurately identify biomarkers. The aim of the ENABLE platform is to provide the Canadian neuroscience community a standardized way of collecting biomarker data from individuals with a range of mood disorders symptoms. In addition, this 'master clinical trial platform' framework will provide a pool of participants who can be recruited into biomarker-based clinical trials.",[28,29,30],"Mood Disorders","Depressive Disorder","Bipolar and Related Disorders","RECRUITING","2026-07-10",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":35},"2023-10-17",{"date":39,"type":23},"2029-03-31",{"name":41,"class":42},"St. Joseph's Healthcare Hamilton","OTHER",9,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":19,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100640452","extended-group-written-exposure-therapy-for-comorbid-ptsd-and-bpd-traits-100640452","NCT07576387","Extended Group Written Exposure Therapy for Comorbid PTSD and BPD (Traits)","Inclusion Criteria:\n\n* Reading and writing proficiency in English\n* Access to an electronic device to attend virtual group meetings\n* Age 18-65\n* Previous diagnosis of Posttraumatic Stress Disorder (PTSD) and Borderline Personality Disorder (BPD)\u002FBPD traits\n* Completion of a DBT skills group via St. Joe's Community Psychiatry Clinic\n\nExclusion Criteria:\n\n* Diagnosis of an active severe substance use disorder or psychotic disorder\n* Untreated active psychotic symptoms, mania, or hypomania\n* Has attempted suicide in the 2 months prior to treatment beginning\n* Has engaged in high-risk self-harm (e.g., cutting, burning, asphyxiation) in the 2 months prior to beginning treatment\n* Has completed Cognitive Processing Therapy or another active PTSD treatment (i.e., prolonged exposure) in the past year","18 Years","65 Years",{"count":53,"type":23},63,"INTERVENTIONAL",[56],"NA","The goal of this open label trial is to evaluate the effectiveness of virtual group extended Written Exposure Therapy (GE-WET) in reducing Post-Traumatic Stress Disorder (PTSD) symptoms in patients with comorbid PTSD and Borderline Personality Disorder (BPD) or BPD traits. GE-WET involves attending weekly 2-hour group WET sessions for the duration of 10 weeks, in which they write about their trauma experience using specific instructions.\n\nThis study will be conducted at St. Joseph's Healthcare Hamilton's Community Psychiatry Clinic with clients wait listed for PTSD treatment (ages 18- 65, any gender, co-morbid PTSD and BPD\u002FBPD traits).\n\nThe main questions this study aims to answer are:\n\nDoes GE-WET reduce PTSD symptoms (based on PCL-5 measures) in this population (outpatient clients ages 18-65 of any gender, with a diagnosis of PTSD and BPD or BPD traits)?\n\nDoes GE-WET result in reduced drop-out rates for this population, compared to that of other evidence-based treatment for PTSD?\n\nWhat are participants subjective experience of GE-WET?",[59,60],"Posttraumatic Stress Disorder (PTSD)","Borderline Personality Disorder (BPD)",[62,63,64,65,66],"borderline personality disorder","posttraumatic stress disorder","written exposure therapy","group therapy","virtual","NOT_YET_RECRUITING","2026-05-04",{"date":70,"type":35},"2026-05-08",{"date":72,"type":23},"2026-06",{"date":74,"type":23},"2028-12",{"name":41,"class":42},1,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":18,"sex":19,"minAge":50,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":54,"phases":86,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100635611","blinking-exercise-study-100635611","NCT07554937","Blinking Exercise Study","Optimizing Blinking Exercises to Improve Dry Eye Disease in Patients With Glaucoma","Inclusion Criteria:\n\n* 18 years of age or older.\n* Those in the intervention group must have a confirmed diagnosis of glaucoma and be using at least one topical antiglaucoma medication.\n* Control participants must be glaucoma suspects who have not yet commenced topical therapy.\n\nExclusion Criteria:\n\n• Glaucoma patients who have had ocular surgery within the previous six months, contact lens wear, systemic inflammatory or autoimmune diseases affecting the ocular surface, or other ocular surface disorders such as severe blepharitis or keratoconjunctivitis sicca.",{"count":85,"type":23},45,[56],"The goal of this clinical trial is to evaluate whether a structured blinking exercise can improve symptoms and signs of dry eye disease (DED) in adults with glaucoma who are using topical intraocular pressure-lowering medications. The study will also assess the effects of the intervention on tear film stability, blink function, and participant adherence to the exercise.\n\nThe main questions this study aims to answer are:\n\nDoes a two-week structured blinking exercise reduce dry eye symptoms, as measured by the Ocular Surface Disease Index (OSDI) and Symptom Assessment in Dry Eye (SANDE) questionnaires? Does the blinking exercise improve objective measures of ocular surface health, including non-invasive tear break-up time (NITBUT) and blink dynamics?\n\nResearchers will compare glaucoma patients receiving topical medications (intervention group) with glaucoma suspects not using topical therapy (control group) to evaluate the effectiveness of the blinking exercise on dry eye outcomes.\n\nParticipants in both groups will receive instruction on a standardized blinking exercise protocol consisting of repeated close-squeeze-open blinking cycles performed three times daily for two weeks. Participants will attend study visits at baseline, 2 weeks (post-intervention), and 4 weeks (follow-up). At each visit, participants will complete validated dry eye questionnaires and undergo non-invasive assessments of tear film stability, blink characteristics, and meibomian gland function. Adherence to the blinking exercise will be monitored using self-reported logs or reminders.",[89,90],"Dry Eye Disease (DED)","Glaucoma",[92,93,90,94,95,96],"Dry Eye Disease","Ocular Surface Disease","Blinking Exercise","Behavioral Intervention","Medication Adherence","2026-04-28",{"date":68,"type":35},{"date":100,"type":23},"2026-08",{"date":102,"type":23},"2027-03",{"name":41,"class":42},{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":19,"minAge":50,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":54,"phases":114,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":76},"100590345","phase-3-multiprofen-cc-to-reduce-pain-in-hand-arthritis-100590345","NCT06966206","Multiprofen-CC to Reduce Pain in Hand Arthritis","Multiprofen-CC to Reduce Pain in Hand Arthritis (MRP-HAND): A Crossover Randomized Controlled Trial","MRP-HAND","Inclusion Criteria:\n\n* Adults (18+)\n* Have been diagnosed with hand osteoarthritis according to American College of Rheumatology criteria\n* Experience pain and\u002For loss of function in one or both hands that interferes with daily life\n* Provide informed consent\n\nExclusion Criteria:\n\n* Unable to consent\n* Unable or unwilling to follow study protocol\n* Known allergy or contraindication to any of the study drugs or their ingredients\n* Have open wounds\u002Fcuts and\u002For skin conditions on the hand area\n* Pregnant or breastfeeding\n* History of impaired kidney or liver function\n* Rheumatoid or other inflammatory arthropathy\n* Hand surgery within the past 6 months or planned within the study period.\n* Use daily opioids (other than short acting codeine) for a chronic pain condition other than hand arthritis",{"count":113,"type":23},42,[115],"PHASE3","This clinical trial aims to find out if using 1 gram of Multiprofen-CC cream on the hands three times a day for 4 weeks can help reduce pain in adults with hand osteoarthritis, compared to a placebo (a cream with no active medicine). The research team will also look at how Multiprofen-CC affects hand function, opioid use, and how patients feel about their overall improvement. In addition, the research team will keep track of any side effects.\n\nParticipants will:\n\n* Use both Multiprofen-CC and a placebo (a cream with no active medicine) during the study, in a random order.\n* Be asked to apply 1 gram of cream to their hands three times a day for 2 weeks, following the manufacturer's instructions.\n* Attend a visit before starting the study, after 2 weeks, and after 6 weeks.\n* Report any symptoms they experience during the study.",[118],"Hand Osteoarthritis",[120,121,122,123,124],"hand osteoarthritis","osteoarthritis","arthritis","topical","multiprofen",{"date":68,"type":35},{"date":127,"type":35},"2026-03-09",{"date":129,"type":23},"2027-08-01",{"name":41,"class":42},{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":139,"minAge":20,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":54,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":149,"completionDateStruct":150,"leadSponsor":152,"locationsCount":76},"100635612","evaluating-the-impact-of-psychoeducation-and-sleep-informed-workshop-targeting-sleep-concerns-in-women-and-individuals-with-premenstrual-dysphoric-disorder-100635612","NCT07554950","Evaluating the Impact of Psychoeducation and Sleep-informed Workshop Targeting Sleep Concerns in Women and Individuals With Premenstrual Dysphoric Disorder","Evaluating the Subjective and Objective Impact of Psychoeducation and Sleep-informed Workshop Targeting Sleep Difficulties in Individuals With Premenstrual Dysphoric Disorder","PMDD","Inclusion Criteria:\n\n1. Aged 16 and above\n2. positive screening for severe PMS and PMDD as per the Premenstrual Severity Screening Tool (PSST)\n3. experiencing sleep difficulties captured by a score of 12 or greater on the Insomnia Severity Index (ISI)\n4. reported regular menstrual cycle (average length of 25-35 days)\n5. not taking psychoactive medication or oral contraceptives or a) participants must be on a stable in dose and type for at least 8 weeks prior to the start of the study and b) medications remain stable throughout the study\n6. fluent in English, minimal grade 8 reading level to understand written materials\n7. individuals must have access to a smart phone or tablet with stable internet connection in order to complete study daily questionnaires\n\nExclusion Criteria:\n\n1. Severe cognitive disability that could impact the understanding of the clinical questionnaires\n2. a diagnosis of schizophrenia or any other primary psychotic disorder or current alcohol or substance use disorders\n3. presence of any unstable medical conditions","FEMALE",{"count":141,"type":23},72,[56],"Premenstrual Dysphoric Disorder (PMDD) is a cyclical mood disorder characterized by emotional, cognitive, physical, and sleep-related symptoms that occur in the days leading up to menstruation and improve shortly after menstruation begins. Although medications are commonly used to treat PMDD, many individuals experience side effects, do not benefit from medication, or prefer non-medication-based approaches. Sleep difficulties are very common in individuals with PMDD and may contribute to mood symptoms, emotional regulation difficulties, and functional impairment. Psychological interventions that focus on sleep, such as sleep psychoeducation and cognitive-behavioural strategies for insomnia, are effective in other mood and anxiety disorders but have not been well studied in PMDD. This study aims to evaluate the feasibility, acceptability, and preliminary effects of a brief, sleep-focused psychoeducation workshop tailored for individuals with PMDD or severe premenstrual symptoms. Information collected in this study may help inform future research and may improve care for individuals with PMDD.",[145,137,146],"Sleep Disturbances","PMS","2026-04-21",{"date":97,"type":35},{"date":72,"type":23},{"date":151,"type":23},"2027-12",{"name":41,"class":42},{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":19,"minAge":50,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":54,"phases":162,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":76},"100619799","the-effects-of-weight-and-nutrition-education-on-weight-control-beliefs-body-image-self-esteem-and-eating-patterns-in-undergraduate-dieters-100619799","NCT07349316","The Effects of Weight and Nutrition Education on Weight Control Beliefs, Body Image, Self-Esteem and Eating Patterns in Undergraduate Dieters","The Effects of Weight Science and Nutrition Education on Weight Control Beliefs, Body Image, Self-Esteem and Eating Patterns in Undergraduate Dieters","Inclusion Criteria:\n\n* Undergraduate students at McMaster University\n* Individuals who are restricting their eating to try and lose weight.\n* Self-identified women\n* Ages 18 or over\n* Normal (or corrected to normal) hearing\n* Normal (or corrected to normal) vision\n\nExclusion Criteria:\n\n\\- Self-identified men",{"count":161,"type":23},150,[56],"People who diet typically believe they can control their weight. People who believe they should control their weight are more likely to have poor body image, low self-esteem and disordered eating. People who believe they should aim for a healthy lifestyle and accept their natural weight have better body image, better self-esteem and less disordered eating. This study will compare three types of education in undergraduate dieters. In the first, the investigators will teach how the body naturally controls weight. In the second, the investigators will teach about healthy eating. In the third, the investigators will teach about how the body naturally controls weight and healthy eating. The study is testing whether teaching about how the body naturally controls weight and healthy eating changes people's beliefs about weight. The study also tests whether changing people's beliefs about weight will change their body satisfaction, their feelings about themselves, and their intention to diet.",[165],"Dietary Restraint",[167,168,169,170,171,172,165],"Weight Control Beliefs","Dieters","Nutrition Counselling","Weight Science","Psychotherapeutic Interventions","Brief Intervention",{"date":174,"type":35},"2026-04-22",{"date":176,"type":35},"2026-01-01",{"date":178,"type":23},"2026-08-31",{"name":41,"class":42},{"id":181,"slug":182,"hasResults":12,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":12,"sex":19,"minAge":50,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":76},"100570459","nsclc-liquid-biopsies-and-exhaled-voc-100570459","NCT06707519","NSCLC Liquid Biopsies and Exhaled VOC","A Prospective, Single Center Study to Test the Validity and Feasibility of Circulating Tumor DNA in Blood, Sputum and Alveolar Fluid, as Well as Exhaled Volatile Organic Compounds as Biomarkers in Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Patient must be at least 18 years of age\n* Patient must be able to provide consent\n* Patients undergoing surgical resection with curative intent for non-small cell lung cancer at St. Joseph's Healthcare Hamilton and Firestone Institute for Respiratory Health.\n\nExclusion Criteria:\n\n* Resection done with non-curative intent or metastatic disease\n* other malignancies\n* Patients with previously treated malignancy less than 5 years prior to current resection (not including skin cancer).",{"count":188,"type":23},210,"The objective of the study is to determine the feasibility of recruiting participants and using sputum, Bronchoalveolar lavage (BAL) and exhaled Volatile Organic Compounds (VOC) in addition to blood, as biological samples for detecting mutations in extracted cell-free DNA in non-small cell lung cancer (NSCLC) patients, before and after surgery, and any recurrence within a 24-month postoperative follow-up period.\n\nThis is a pilot feasibility study, proposed as a 24-month prospective, single-center, non-interventional, observational trial with NSCLC-adenocarcinoma patients indicated for resection surgery with curative intent.",[191,192],"Lung Cancer","Circulating Tumor DNA",{"date":174,"type":35},{"date":195,"type":35},"2023-02-01",{"date":197,"type":23},"2027-12-29",{"name":41,"class":42},{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":139,"minAge":50,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":54,"phases":207,"briefSummary":208,"conditions":209,"keywords":212,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":76},"100631019","cognitive-processing-therapy-for-childbirth-related-post-traumatic-stress-disorder-100631019","NCT07495228","Cognitive Processing Therapy for Childbirth-Related Post-Traumatic Stress Disorder","CB-PTSDCPT","Inclusion Criteria:\n\n* women\u002Fbirthing people aged 18 years and older who are fluent in English (able to speak\u002Funderstand and read English), and who are at least one month postpartum\n* either indicate clinical levels of PTSD related to a traumatic birth (i.e., 31 or higher on the PCL-5) or endorse significant distress or impairment as a result of their traumatic childbirth experience\n* not receiving concurrent psychological treatment\n* not taking psychoactive medication or if taking medications, are stable in dose and type for at least 8 weeks prior to the study (as per Canadian psychiatric guidelines; McQueen et al., 2016) and remain stable throughout the study\n\nExclusion Criteria:\n\n* severe depression\u002Fsuicidality requiring acute intervention\n* medication changes in dose or type",{"count":5,"type":23},[56],"The goal of this clinical trial is to determine whether participation in an individual 8-session cognitive processing therapy (CPT) is feasible, acceptable, and leads to clinically meaningful trauma symptom reduction in individuals experiencing childbirth-related trauma.\n\nThe main questions it aims to answer are:\n\n1. Is it feasible for women and birthing people to attend and complete an 8-session course of CPT delivered virtually within a specialized women's mental health clinic?\n2. Do participants find this modified 8-session CPT protocol acceptable and helpful?\n3. Does the treatment lead to clinically meaningful reductions in childbirth-related posttraumatic stress and related symptoms?\n\nParticipants will be asked to:\n\n1. Attend 8 weekly sessions of individual CPT for childbirth-related trauma\n2. Complete a self-report measure of trauma symptoms weekly (i.e., the PCL-5)\n3. Complete additional symptom questionnaires at baseline, post-treatment, and at one-month follow-up.\n4. Complete a brief qualitative interview one week after treatment to share feedback on their experience",[210,211],"Childbirth-Related Posttraumatic Stress Disorder","Childbirth-related Trauma",[213,214,215,210,216,217,218],"Postpartum","Posttraumatic Stress Disorder","Childbirth","Trauma","Cognitive Processing Therapy","mothers","2026-03-22",{"date":221,"type":35},"2026-03-27",{"date":223,"type":23},"2026-04-01",{"date":225,"type":23},"2028-04-01",{"name":41,"class":42},{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":19,"minAge":50,"maxAge":235,"enrollmentInfo":236,"targetDuration":4,"studyType":54,"phases":238,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":257,"locationsCount":258},"100619253","correctional-service-of-canada-pilot-trial-of-digital-substance-use-disorder-interventions-process-100619253","NCT07342218","Correctional Service of Canada Pilot Trial of Digital Substance Use Disorder Interventions (PROCESS)","Pilot Trial of Digital Substance Use Disorder Interventions to Prevent Post-release Substance Use Disorder Relapse in Offenders in Correctional Service of Canada Custody","PROCESS","Inclusion Criteria:\n\n* Individuals who have previously served custodial services in the Correctional Services of Canada (csc).\n* Individuals who have a history of substance use problems (i.e., determined by them not being allowed to use substances as part their parole terms)\n* Individuals who current reside in a Community Correctional Centre or Community-Based Residential Facility\n* Individuals between 18-55 years old\n\nExclusion Criteria:\n\n\\- Individuals who have never served a custodial sentence with the CSC","55 Years",{"count":237,"type":23},20,[56],"Problems with substance use are common in prisoners. Since most substances are still illegal in Canada, substance use problems can increase the risk for re-incarceration. Although research suggests that treatment may reduce these risks, they are still rarely used in correctional settings. This pilot study will examine the feasibility and usefulness of two digital treatments for substance use problems in individuals recently released from prison. The investigators will compare engagement across both treatments over a 6-month period, and assess the rates of substance use relapse and re-incarceration.",[241],"Substance Use Disorder (SUD)",[243,244,245,246,247,248,249,250],"incarceration","federal offender","substance use disorder","cognitive behavioural therapy","mindfulness","digital treatment","substance use treatment","pilot trial","2026-03-12",{"date":253,"type":35},"2026-03-13",{"date":255,"type":35},"2026-02-25",{"date":102,"type":23},{"name":41,"class":42},4,{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":139,"minAge":50,"maxAge":51,"enrollmentInfo":266,"targetDuration":4,"studyType":54,"phases":268,"briefSummary":269,"conditions":270,"keywords":273,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":76},"100612231","resolving-early-life-stress-psychotherapy-outcomes-and-neurobiology-in-complex-depression-100612231","NCT07250893","Resolving Early Life Stress: Psychotherapy Outcomes and Neurobiology in Complex Depression","RESPOND","Inclusion Criteria:\n\n* Adults 18 years old or older\n* At or above 18 on HAM-D, indicative of moderate-severe depressive symptoms\n* Any childhood (before 18 years old) adversity as indicated by scores on the CECA q and ACES q\n\nExclusion Criteria:\n\n* Individuals who meet for PTSD diagnosis from a criterion A trauma occurring in adulthood without a history of ELA\n* Individuals experiencing active mania or psychosis\n* Individuals with an active substance use disorder\n* Individuals presenting with active suicide risk (plan, intention, means) indicative of a need for higher level care\n* Individuals in current psychotherapeutic treatment (defined as having engaged in consistent psychotherapy within the last 3 months)",{"count":267,"type":23},50,[56],"The RESPOND trial explores the link between early life adversity and later life depressive symptoms. The investigators have designed a new psychological therapy tailored to address the symptoms that can be caused by difficult experiences in early life. These symptoms include low mood, emotional dysregulation, and distressing thoughts and beliefs related to difficult or traumatic experiences. The investigators would like to see if this new therapy helps people feel better. The investigators are also studying the biological changes that can occur as a result of early life adversity, and how this therapy may influence those changes. To do this, the investigators ask questions about participants' physical and mental health and take blood samples.",[271,272],"Depression - Major Depressive Disorder","Childhood Traumas",[274,275,276,277],"Early life adversity","Depression","Emotional dysregulation","Childhood trauma","2026-01-30",{"date":280,"type":35},"2026-02-03",{"date":282,"type":35},"2025-10-25",{"date":284,"type":23},"2028-08-15",{"name":41,"class":42},{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":19,"minAge":50,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":54,"phases":294,"briefSummary":297,"conditions":298,"keywords":300,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":76},"100565126","phase-1-3-dimensional-virtual-reality-modelling-with-intravascular-indocyanine-green-fluorescence-mapping-for-targeted-pulmonary-segmental-resection-trial-100565126","NCT06638125","3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial","Inclusion Criteria:\n\n* Age \\>\u002F= 18 years\n* Tumour size \\\u003C 3 cm\n* Clinical Stage 1 Non-Small Cell Lung Cancer (NSCLC)\n* CT-imaging confirming that the tumour is confined to one broncho-pulmonary segment, rendering the patient a candidate for segmental resection.\n\nExclusion Criteria:\n\n* Hypersensitivity or allergy to ICG, sodium iodide, or iodine\n* Women who are currently pregnant or breastfeeding; or women of childbearing potential who are not currently taking adequate birth control.",{"count":293,"type":23},89,[295,296],"PHASE1","PHASE2","With the advent of CT screening for lung cancer, an increasing number of NSCLCs are being detected at very early stages, and the demand for pulmonary segmentectomy is rising rapidly. As such, there is a need to develop new surgical techniques to facilitate minimally invasive pulmonary segmentectomy, as segmentectomy may provide a number of significant advantages over lobectomy for patients presenting with early-stage lung cancer, or for patients unable to undergo a full lobectomy due to existing comorbidities. This study will provide the first case series using preoperative 3D virtual reality (VR) anatomical planning (Elucis) added to ICG and NIF-guided robotic segmentectomy to date and will be the first reported use of Elucis-guided targeted pulmonary segmental resection in Canada. As lung cancer is the most frequently fatal cancer in North America, many thousands of patients will be able to benefit from this operation every year.\n\nIf successful, this project will establish a novel operation that has the potential of increasing the rates of success for segmental resection. This will allow for further research that will externally validate this technique and ensure that it is reproducible in other centres by other surgeons. As segmental resection is the new standard of care for surgical management of early-stage NSCLC, and because lung cancer is the most frequently fatal cancer in North America, many thousands of patients will be able to benefit from this operation every year.\n\nEqually importantly, the investigators believe that this method will enable them to develop a new way of teaching lung resections, in a manner that is more effective for learners. Further research on the role of VR in teaching lung cancer surgery will very likely be a downstream effect of developing this surgical method.",[299],"Non Small Cell Lung Cancer",[301,302,303],"3-Dimensional Virtual Reality Modelling","Intravascular Indocyanine Green Fluorescence Mapping","Pulmonary Segmental Resection","2026-01-29",{"date":306,"type":35},"2026-02-02",{"date":308,"type":23},"2026-12-01",{"date":310,"type":23},"2028-12-31",{"name":41,"class":42},{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":19,"minAge":50,"maxAge":319,"enrollmentInfo":320,"targetDuration":4,"studyType":54,"phases":322,"briefSummary":323,"conditions":324,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":325,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":76},"100542835","totally-robotic-versus-surgeon-assisted-robotic-lung-resection-for-early-stage-nsclc-100542835","NCT06348030","Totally Robotic Versus Surgeon-Assisted Robotic Lung Resection For Early-Stage NSCLC","Totally Robotic Versus Surgeon-Assisted Robotic Lung Resection For Early-Stage Non-Small Cell Lung Cancer: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 120 years at time of consent\n* Ability to speak and understand English\n* Clinical stage I, II or IIIa NSCLC\n* Candidate for RTS, as determined by the operating surgeon\n\nExclusion Criteria:\n\n* Anticoagulation with inability to cease anticoagulant therapy prior to surgery\n* Incurable coagulopathy\n* Systemic vascular disease or vasculitis\n* Not a candidate for RTS","120 Years",{"count":321,"type":23},120,[56],"Robotic-assisted thoracoscopic surgery (RTS) is safe and effective for patients with early-stage non-small cell lung cancer (NSCLC). During RTS, division, dissection, and sealing of lung tissue, bronchi, and blood vessels can be performed using handheld staplers with assistance from a bedside surgeon (Surgeon-Assisted), or totally robotically with robotic staplers and energy devices by the console surgeon (Totally Robotic). Totally Robotic lung resection enables the operating surgeon to perform the case independently, but its implication on costs and patient outcomes remains unknown. There also is, however, a lack of prospective research evaluating the costs of the two methods for dissection and vessel sealing in RTS. This RCT aims to evaluate the costs and perioperative patient outcomes of Totally Robotic lung resection using the Vessel Sealer Extend energy device (for vessels \\\u003C7mm) and the SureForm robotic stapler (Intervention) versus Surgeon-Assisted robotic lung resection using the Signia stapler (Control) during RTS for NSCLC using the da Vinci system.",[191],{"date":306,"type":35},{"date":327,"type":23},"2026-09",{"date":329,"type":23},"2028-04",{"name":41,"class":42},{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":19,"minAge":50,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":54,"phases":340,"briefSummary":341,"conditions":342,"keywords":345,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":357,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":76},"100358905","phase-1-synapse-3d-with-intravascular-indocyanine-green-100358905","NCT03953144","Synapse 3D With Intravascular Indocyanine Green","Synapse 3D With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial: A Phase I Safety and Feasibility Trial","Inclusion Criteria:\n\n* Tumour size \\\u003C3 cm\n* Clinical Stage 1 Non-Small Cell Lung Cancer (NSCLC)\n* CT-imaging confirming that the tumour is confined to one broncho-pulmonary segment, rendering the patient a candidate for segmental resection.\n\nExclusion Criteria:\n\n* Hypersensitivity or allergy to ICG, sodium iodide, or iodine\n* Women who are currently pregnant or breastfeeding; or women of childbearing potential who are not currently taking adequate birth control.\n* Patients with clinical evidence of N1 or N2 disease on preoperative imaging\n* Pulmonary Function tests demonstrating Forced Expiratory Volume in 1s (FEV1) or diffusion capacity of the lung for carbon monoxide (DLCO) less than or equal to 30% of predicted.",{"count":339,"type":23},32,[295,296],"With the advent of CT screening for lung cancer, an increasing number of NSCLCs are being detected at very early stages, and the demand for pulmonary segmentectomy is rising rapidly. As such, there is a need to develop new surgical techniques to facilitate minimally invasive pulmonary segmentectomy, as segmentectomy may provide a number of significant advantages over lobectomy for patients presenting with early-stage lung cancer, or for patients unable to undergo a full lobectomy due to existing comorbidities. This study will provide the first case series using preoperative 3D anatomical planning (Synapse 3D) added to ICG and NIF-guided robotic segmentectomy to date and will be the first reported use of Synapse 3D-guided targeted pulmonary segmental resection in Canada. As lung cancer is the most frequently fatal cancer in North America, many thousands of patients will be able to benefit from this operation every year.",[343,344],"Non-small Cell Lung Cancer","Primary Neoplasm",[346,191,347,348,349,350,351,352,353,354,355,356],"Segmentectomy","Robotic Surgery","3D Modelling","CT Imaging","Near-Infrared Fluorescence","IC-GREEN","Surgical Planning","Indocyanine Green","Early-Stage Lung Cancer","Surgical Mapping","Lung Preservation",{"date":306,"type":35},{"date":359,"type":35},"2022-12-01",{"date":361,"type":23},"2026-12-31",{"name":41,"class":42},{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":12,"sex":19,"minAge":50,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":54,"phases":372,"briefSummary":373,"conditions":374,"keywords":375,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":382,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":76},"100252892","phase-1-near-infrared-fluorescence-guided-robotic-pulmonary-segmentectomy-for-early-stage-lung-cancer-100252892","NCT02570815","Near-Infrared Fluorescence Guided Robotic Pulmonary Segmentectomy for Early Stage Lung Cancer","Near-Infrared Fluorescence Guided Robotic Pulmonary Segmentectomy for Early Stage Lung Cancer: Analysis of Accuracy and Added Value","Inclusion Criteria:\n\n1. Age \\> 18 years\n2. Tumor size \\\u003C3 cm\n3. Clinical Stage 1 Non-Small Cell Lung Cancer (NSCLC)\n4. CT-imaging confirming that the tumour is confined to the one broncho-pulmonary segment, rendering the patient a candidate for segmental resection.\n\nExclusion Criteria:\n\n1. Hypersensitivity or allergy to ICG, sodium iodide or iodine\n2. Women who are currently pregnant or are breast feeding; or women of child bearing potential who are not currently taking adequate birth control.",{"count":371,"type":23},250,[295],"Lungs are made up of individual lobes. When a lung cancer tumour is detected in one of these lobes, surgeons typically perform a Lobectomy. A Lobectomy is the surgery most commonly done to treat early-stage lung cancer and requires removal of an entire lobe of the lung, which removes a large amount of lung tissue For patients with small tumours saving as much healthy lung tissue as possible is important. Each lobe of the lung has smaller sections called segments. When a lung cancer is in one of these segments, it is possible to remove that segment, without removing the entire lobe. This surgery is called a segmentectomy. Compared to a lobectomy, a segmentectomy saves a larger amount of healthy lung tissue.\n\nWith the advances in screening technology for lung cancer tumours, an increasing amount of very small lung cancer tumours are being found, and the demand for segmentectomy is increasing. A segmentectomy is a hard surgery to perform robotically because it is difficult to view the tissue lines that separate each segment within the lobe. As a result, it is difficult for the surgeon to see exactly which pieces of tissue should be removed. Because of these challenges, many patients having robotic surgery will have a lobectomy, even if a full lobectomy is not needed.\n\nNear-Infrared Fluorescence (NIF) using indocyanine green (ICG) fluorescent dye is a recent advancement in the robotic platform of robotic surgery. The surgeon will view the CT scan to determine which segment the tumour is located in. Once identified, the surgeon will isolate the segment by cutting off the blood supply to that segment. Then ICG will be injected into a vein. It is expected that the entire lung, except the isolated segment, which will remain 'dark' as it was isolated from blood supply, will fluoresce, giving off a green hue when viewed with the da Vinci Firefly camera. The surgeon will identify 'dark' segment, and will remove it. A pathologist will examine the excised tissue to ensure that the tumour was removed in its entirety. Once confirmed, the surgeon will end the procedure. If the pathologist determines that the segment removed did not contain the entire tumour, then the surgeon will perform a routine lobectomy. This ensures patient safety and confirms that all participants will have the entire tumour removed from their lung.",[343],[376,377,378,379,351,380,381],"lung cancer","segmentectomy","robotic surgery","near-infrared fluorescent","indocyanine green","early-stage lung cancer",{"date":306,"type":35},{"date":384,"type":4},"2016-10",{"date":386,"type":23},"2026-12",{"name":41,"class":42},{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":54,"phases":397,"briefSummary":398,"conditions":399,"keywords":402,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":419,"leadSponsor":421,"locationsCount":76},"100622772","a-brief-cannabis-use-psychoeducation-intervention-for-eating-disorder-patients-100622772","NCT07387965","A Brief Cannabis Use Psychoeducation Intervention for Eating Disorder Patients","A Brief Psychoeducation Intervention to Address Cannabis Use Amongst Patients Seeking Eating Disorder Treatment: A Single Blind Randomized Control Trial","Inclusion Criteria:\n\n* A patient of St. Joseph's Healthcare Hamilton Eating Disorder Program (i.e. is currently seeking eating disorders treatment)\n* Participant has been diagnosed with an eating disorder\n* Aged 16+\n* Understands written and spoken English\n\nExclusion Criteria:\n\n* Has not been diagnosed with an eating disorder\n* Under the age of 17\n* Does not understand written and spoken English",{"count":396,"type":23},80,[56],"The goal of this clinical trial is to learn if providing eating disorder patients with education about the consequences of cannabis (marijuana) use on mental health, gastrointestinal symptoms, eating disorder symptoms, and eating disorder treatment effectiveness increases their knowledge about the cannabis use consequences, intention to reduce cannabis use, and motivation to seek treatment for their cannabis use. The main questions this study aims to answer are:\n\n1. Does education about consequences of cannabis use increase eating disorder patients' knowledge about the risks of cannabis use?\n2. Does education about the consequences of cannabis use increase intention to reduce cannabis use and seek cannabis use treatment among those with eating disorders?\n3. Does cannabis use interfere with how successful eating disorder treatment is for eating disorder patients?\n\nAll participants will receive 20 weeks of eating disorder treatment. In week 1 of treatment, participants will either be assigned to receive education about cannabis use consequences, or be assigned to a control condition where they receive education about consequences of poor sleep. Participants will be asked to complete a number of questionnaires that measure knowledge about cannabis use consequences, intention to reduce use and seek cannabis use treatment, eating disorder symptoms, and cannabis use habits. Researchers will assess how effective providing education about cannabis use consequences is on changing knowledge about cannabis use risks, intention to reduce use, and intention to seek cannabis use treatment. It will also be examined if effectiveness of eating disorder treatment is related to cannabis use habits.",[400,401],"Eating Disorders","Cannabis Use",[403,404,405,406,407,408,409,410,411,412,413,414],"single blind","single blind randomized control trial","randomized control trial","eating disorders","cannabis use","psychoeducation","brief intervention","marijuana","cannabis","binge eating disorder","anorexia nervosa","bulimia nervosa","2026-01-27",{"date":417,"type":35},"2026-02-04",{"date":417,"type":23},{"date":420,"type":23},"2028-02-04",{"name":41,"class":42},{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":19,"minAge":50,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":432,"conditions":433,"keywords":440,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":453,"locationsCount":454},"100621718","do-qt-prolonging-drugs-cause-major-adverse-cardiac-events-in-hospitalized-adults-100621718","NCT07374263","Do QT-Prolonging Drugs Cause Major Adverse Cardiac Events in Hospitalized Adults?","Do 'Known' QT-prolonging Medications Cause Major Adverse Cardiac Events in Hospitalized Adults? The QTP-MACE Study","QTP-MACE","Inclusion Criteria:\n\n* Adult patients 18 years of age or older\n* Admitted to St. Joseph's Healthcare Hamilton or GEMINI hospitals between December 2017 and March 2025\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years old\n* Outpatient encounters",{"count":431,"type":23},990000,"There are 28 non-cardiology medications from multiple families costing more than $13 billion annually in Canada, categorized as 'Known' QT-prolonging medications (QTPmeds) based on very low levels of evidence. The association between many commonly used medications listed as known QTPmeds and actual major adverse cardiac events (MACE) is weak. Meanwhile, QTPmeds-related warnings are ubiquitous in every healthcare setting, triggering 'hard stop' disruption millions of times per day to front line clinicians. Poor quality medication safety alerts are increasingly recognized as a source of inferior patient care and provider burnout which detracts from healthcare sustainability.\n\nIn this study, anonymized hospital electronic medical record data from more than 990,000 adult patients across Ontario will be used to compare patients who experience MACE with those who do not, measuring their real-time exposure to QT-prolonging drugs. Additionally, machine-learning techniques will also be used to find which patient or treatment factors best predict risk.\n\nThe objectives of this study are to 1) Investigate whether exposure to one or more 'Known' QTPmed is associated with an increased risk of MACE after adjusting for confounders; and 2) Identify predictors and their relative importance for QTPmeds-associated MACE.\n\nIn summary, QT-prolonging medications have the potential to cause very serious adverse events, including death. However, it is not sufficiently clear which patients under which circumstances suffer events, or when is QT prolongation a useful surrogate marker for harm. Meanwhile, ubiquitous medication alerts related to QT-prolonging medications are at best imprecise and at worst, misleading, costly and potentially dangerous. Now that data resources are available with the data elements, structure and sample size required to rigorously assess this association, this study will address this question to improve patient safety, provider satisfaction and the cost-effectiveness of care.",[434,435,436,437,438,439],"Acquired Long QT","Ventricular Arrhythmias","Torsades de Pointes","Syncope","Medication Safety","MACE",[441,442,443,444,445,446],"Medication safety","QT interval prolongation","Long QT syndrome","Ventricular arrhythmia","Torsades de pointes","Major adverse cardiac events","2026-01-24",{"date":449,"type":35},"2026-01-28",{"date":451,"type":35},"2025-02-01",{"date":151,"type":23},{"name":41,"class":42},2,{"id":456,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":457,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":459,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":464,"leadSponsor":466,"locationsCount":43},"100547441",{"count":458,"type":23},900,[28,29,30],"2026-01-20",{"date":462,"type":35},"2026-01-22",{"date":37,"type":35},{"date":465,"type":23},"2026-03-31",{"name":41,"class":42},{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":139,"minAge":50,"maxAge":4,"enrollmentInfo":474,"targetDuration":4,"studyType":54,"phases":475,"briefSummary":476,"conditions":477,"keywords":480,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":494,"locationsCount":454},"100613147","psychological-and-physiological-impact-of-a-mindfulness-based-intervention-on-anxiety-disorders-during-the-postpartum-period-100613147","NCT07262801","Psychological and Physiological Impact of a Mindfulness-based Intervention on Anxiety Disorders During the Postpartum Period","Evaluating the Psychological and Physiological Impact of a Mindfulness-based Intervention on Anxiety Disorders During the Postpartum Period: A Proof of Concept Trial","Inclusion Criteria:\n\n* mothers\u002Fbirthing parents 18 years and older who are between 0-12 months postpartum\n* principal diagnosis of an anxiety disorder as per the Diagnostic Assessment Research Tool (DART; Schneider et al., 2022), with or without comorbid depression\n* no concurrent psychological treatment\n* not taking psychoactive medication or a) medications are stable in dose and type for at least 8 weeks prior to the study (as per Canadian psychiatric guidelines; McQueen et al., 2016) and b) medications remain stable throughout the study\n* fluent in English, minimal grade 8 reading level.\n\nExclusion Criteria:\n\n* severe depression\u002Fsuicidality requiring acute intervention\n* women with psychotic or current alcohol or substance use disorders\n* suffering from severe claustrophobia\n* metallic objects in body (metal implants, pacemakers)\n* currently pregnant",{"count":267,"type":23},[56],"Postpartum anxiety (PPA) affects up to 20% of mothers in the first year after delivery, with mothers often reporting both psychological and physical symptoms. Present non-pharmacological interventions are effective at improving some psychological aspects of PPA such as anxiety, depressive mood, and distress. However, current interventions are not effective in improving emotion regulation (ER), something that many with PPA experience impairment in. Current interventions also seldom target the physical aspects of anxiety, such as bodily awareness - sensing and understanding internal signals in the body (e.g., sensing a fast heartbeat). There is a link between ER and bodily awareness, however psychological interventions that target both these aspects have not been investigated in the PPA population. As a result, a mind-body intervention targeting both ER and bodily awareness is needed to offer a more holistic treatment option.\n\nThe purpose of the proposed study is to test the effectiveness of a 4-week mindfulness intervention on anxiety symptoms, ER, and bodily awareness in those with PPA. We will use self-report questionnaires alongside brain imaging (functional magnetic resonance imaging; fMRI) to evaluate the effectiveness. Combining both subjective and objective measures will provide greater confidence in our findings, ensuring a more comprehensive understanding of the intervention's impact. Self-report questionnaires will be administered at enrolment, immediately post-intervention, and 4 weeks post-intervention. Brain imaging will be conducted at enrolment and immediately post-intervention. We believe this intervention will lead to improvements in anxiety symptoms, ER, and bodily awareness on the questionnaires and fMRI scans.\n\nIf effective, the proposed mindfulness intervention will target a broader range of psychological and physical symptoms, and reduce the negative impact of PPA on mothers and their infants in Canada and beyond.",[478,479],"Postpartum Anxiety","Anxiety Disorders",[481,482,218,247,483,484,485,486,487],"postpartum anxiety","anxiety disorders","mindfulness-based intervention","emotion regulation","interoception","fMRI","resting state functional connectivity","2025-12-01",{"date":490,"type":35},"2025-12-04",{"date":492,"type":23},"2025-12",{"date":327,"type":23},{"name":41,"class":42},{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":19,"minAge":503,"maxAge":504,"enrollmentInfo":505,"targetDuration":4,"studyType":54,"phases":507,"briefSummary":508,"conditions":509,"keywords":511,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":76},"100595926","deep-rtms-for-mild-neurocognitive-disorder-in-older-adults-100595926","NCT07038798","Deep rTMS for Mild Neurocognitive Disorder in Older Adults","Feasibility and Tolerability of Deep Repetitive Transcranial Magnetic Stimulation for Mild Neurocognitive Disorder in Older Adults: A Pilot Study (DeepMIND)","Deep MIND","Inclusion Criteria:\n\n* 60 - 90 years old\n* Able to provide informed consent to participate in the study\n* Subjective concern of mild decline in cognitive function over the past year\n* Mild impairment in cognitive performance\n* Preserved independence in everyday activities\n* Independently mobile (e.g., participants must be able to get in and out of a chair on their own)\n* Participants will be required to be on stable dosages of other psychotropic medications for at least 4 weeks prior to screening\n\nExclusion Criteria:\n\n* Currently receiving treatment or subjective need for treatment for bipolar I or II disorder; psychotic disorder\n* Active suicidal behavior\n* Severe depression and\u002For anxiety\n* Other neurological or psychiatric disorders accounting for the cognitive deficits\n* Impairment in basic and\u002For instrumental activities of daily living\n* Substance use disorder (other than tobacco use disorder) in the past 3 months before entering the study\n* Traditional contraindications to rTMS: Intracranial or metal implants in the head or nearby regions, excluding the mouth, that cannot be safely removed; History of epilepsy or seizures; Active unstable medical condition (recent laboratory and neuroimaging alterations, delirium); Pacemaker and\u002For implantable cardioverter-defibrillators; current use of bupropion, treatment with equivalent benzodiazepine dose to lorazepam \\>2 mg\u002Fday\n* People with severe literacy, visual, or hearing issues that affect the ability to engage in the interviews\n* People with recurring migraines or headaches (weekly or more)\n* Frequent dizziness\u002Fvertigo\n* Individuals residing beyond the borders of the Greater Hamilton Area and its neighbouring vicinities","60 Years","90 Years",{"count":506,"type":23},30,[56],"This study aims to: (1) assess the feasibility and tolerability of three deep transcranial magnetic stimulation (dTMS) coils H1, H4, and H7 in older adults with mild neurocognitive disorder (mild NCD); and (2) evaluate changes in cognition through neuropsychological testing, brain activity through EEG, and mood and sleep through self-report questionnaires. Participants will be assigned to one of three arms: H1- coil vs. H4-coil vs. H7-coil, and all participants will complete assessments examining dTMS side effects, mental health symptoms, and cognition. EEG, questionnaires, and CNS vital signs will be measured at baseline, midpoint (after 10th session- before dTMS treatment on visit 11), and end point, as well as follow up. Collectively, the study will address the absolute and differential feasibility and tolerability of the H1, H4 and H7 coils to provide preliminary data for a future randomized controlled trial comparing this novel intervention to a sham stimulation (placebo) control.",[510],"Mild Neurocognitive Disorder",[510,512,513,514,515,516,517,518,519,520,521],"Mild NCD","Mild Cognitive Impairment","Deep Transcranial Magnetic Stimulation","deep TMS","dTMS","H coil","H-coil","H1-coil","H4-coil","H7-coil","2025-09-30",{"date":524,"type":35},"2025-10-06",{"date":526,"type":35},"2025-08-26",{"date":528,"type":23},"2027-01",{"name":41,"class":42},{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":536,"eligibilityCriteria":537,"healthyVolunteers":12,"sex":19,"minAge":50,"maxAge":4,"enrollmentInfo":538,"targetDuration":4,"studyType":54,"phases":540,"briefSummary":541,"conditions":542,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":552},"100536033","phase-3-non-invasive-ventilation-and-dexmedetomidine-in-critically-ill-adults-100536033","NCT06259565","Non-invasive Ventilation and Dexmedetomidine in Critically Ill Adults","Non-invasive Ventilation and Dexmedetomidine in Critically Ill Adults: An International Pragmatic Randomized Controlled Trial (inDEX Trial)","inDEX","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Patient receiving any NIV modality for acute respiratory failure of any etiology\n3. Admitted to ICU, PACU, step-down unit (surgical or medical), or emergency department(with planned admission to a monitored setting) or equivalent unit where hemodynamics and respiratory status can be monitored, and NIV is permitted; and\n4. Presence of one or more of the following after optimized NIV treatment:\n\n   1. Agitation (Defined as a Richmond Agitation and Sedation Scale \\[RASS\\] score of ≥+2 or a Riker Sedation-Agitation Scale \\[SAS\\] score of ≥5) (Appendix 1 Table 2 and Table 3)\n   2. Patient expresses intolerance or requests removal of NIV secondary to self-reported discomfort, anxiety, or claustrophobia\n   3. Other reason that the physician judges the patient to be intolerant of NIV or agitated, not captured above, or feels that the patient would benefit from titrated sedation for other reasons.\n\nExclusion Criteria:\n\n1. Absence of a functioning pacemaker with one of the following: a-Persistent bradycardia defined as a heart rate (HR) ≤60bpm; b-Second or third-degree heart block; or c- Tachybrady syndrome\n2. Persistent hypotension, defined as a mean arterial pressure (MAP) ≤65mmHg despite volume resuscitation and vasopressors\n3. Imminent need for endotracheal intubation as determined by healthcare team\n4. Patient's goals of care do not include intubation and IMV\n5. Patient is not for vasopressors or inotropic support\n6. Death is deemed imminent and inevitable\n7. Patient is currently on a dexmedetomidine infusion for a duration of \\> 12 hours\n8. Previously enrolled in the inDEX trial\n9. Acute liver failure with hepatic encephalopathy INR \\> 3 and\u002For bilirubin \\> 300\n10. Current pregnancy or breast feeding\n11. Known allergy to dexmedetomidine\n12. Patients receiving Amphotericin B or Diazepam\n13. Treating physician does not believe that participation in the trial is in the best interest of the patient (reasons for refusal will be captured)",{"count":539,"type":23},846,[115],"Non-Invasive ventilation (NIV) is a life saving intervention for patients with acute respiratory failure (ARF). Some patients are not able to tolerate the NIV intervention and ultimately fail, requiring the use of invasive mechanical ventilation (IMV) and intubation. Sedation may improve a patient's NIV tolerance. However, this practice has not been adopted by intensivists as the risk of over-sedation resulting in respiratory depression, inability to protect the airway, and inadvertent need for intubation are all large deterrents of sedative use in NIV.\n\nThe Non-invasive Ventilation and Dexmedetomidine in Critically Ill Adults: a Pragmatic Randomized Controlled Trial (inDEX) is looking to evaluate the effectiveness of dexmedetomidine compared to placebo in reducing non-invasive ventilation failures in patients admitted to the hospital with acute respiratory failure.",[543],"Non-Invasive Ventilation","2025-09-03",{"date":546,"type":35},"2025-09-10",{"date":548,"type":35},"2025-07-29",{"date":550,"type":23},"2030-01-31",{"name":41,"class":42},6,{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":559,"eligibilityCriteria":560,"healthyVolunteers":12,"sex":19,"minAge":51,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":54,"phases":563,"briefSummary":565,"conditions":566,"keywords":568,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":573,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":76},"100535403","phase-4-early-sedation-with-dexmedetomidine-vs-placebo-in-older-ventilated-critically-ill-patients-100535403","NCT06251375","Early Sedation With Dexmedetomidine vs. Placebo in Older Ventilated Critically Ill Patients","Sedation Practice in Intensive Care Evaluation (SPICE IV) Early Sedation With Dexmedetomidine vs. Placebo in Older Ventilated Critically Ill Patients: A Prospective, Multi-Centre, Double-Blind, Randomized, Controlled Trial","SPICEIV","Inclusion Criteria:\n\n1. Age ≥ 65 years\n2. Intubated and receiving invasive mechanical ventilation in an intensive care unit\n3. The treating clinicians believe that the patient will remain intubated and ventilated until the day after tomorrow (i.e. unlikely to be extubated the following day)\n4. The patient requires immediate ongoing sedative medication for comfort, safety and to facilitate the delivery of life support measures.\n\nExclusion Criteria:\n\n1. Has been intubated (excluding time spent intubated within an operating theatre or transport) for greater than 12 hours, with an additional 6-hour grace period, a total of 18 hours, in an intensive care unit\n2. Proven or suspected acute primary brain lesion such as traumatic brain injury, haemorrhage, stroke, or hypoxic brain injury\n3. Proven or suspected spinal cord injury or other pathology that may result in permanent or prolonged weakness\n4. Admission as a consequence of a suspected or proven drug overdose or burns\n5. Administration of or need for ongoing neuromuscular blockade\n6. A mean arterial blood (MAP) pressure that is less than 50 mmHg, despite adequate resuscitation and vasopressor support at time of randomization\n7. Heart rate less than 55 beats per minute or a high grade atrio-ventricular block in the absence of a functioning pacemaker\n8. Known sensitivity to dexmedetomidine\n9. Acute fulminant hepatic failure with EITHER\n\n   1. hepatic encephalopathy OR\n   2. bilirubin (\\>300 µmol\u002Fl) and INR (\\>3.5), or both, without prior hepatic dysfunction.\n10. Receiving full time residential nursing care\n11. Death is deemed both imminent and inevitable and either the attending physician, patient or substitute decision maker is not committed to active treatment\n12. Underlying disease that makes survival to 90 days unlikely\n13. Previously enrolled in the SPICE IV study",{"count":562,"type":23},300,[564],"PHASE4","Sedation remains a ubiquitous and crucial component of intensive care treatments in critically ill mechanically ventilated patients. Sedation relieves anxiety, reduces distress, and promotes tolerance of endotracheal intubation and associated life-sustaining interventions such as mechanical ventilation, cardiovascular assistance, and renal support. Thus, choosing the optimal sedative agent is vital to patient comfort, safety, and survival. Despite more than 20 years of intensive care sedation research, there is still no consensus on what constitutes best sedation practice. The Society of Critical Care Medicine, the premier critical care organisation in North America, published the 2018 Clinical Practice Guidelines on the management of Pain, Agitation\u002FSedation, Delirium, Immobility and Sleep (PADIS) disruption (chaired by our primary applicant W.A.) and issued weak recommendations to provide analgesia before sedation, to target light sedation whenever clinically feasible, and to use either dexmedetomidine or propofol over midazolam for the sedation of mechanically ventilated critically ill patients. Similarly, the American Thoracic Society produced a set of Clinical Practice Guidelines to promote liberation and weaning from mechanical ventilation in critically ill patients, with weak recommendations for the use of non-benzodiazepines as primary sedatives and to target light sedation when clinically possible. A weak recommendation was issued in an Intensive Care Medicine Rapid Practice Guideline published in 2022 to use dexmedetomidine over propofol for sedation of critically ill adults, if the desired outcome is a reduction in delirium. These guidelines, however, do not consider age-dependent pharmacokinetics and pharmacodynamics, illness severity, timing of sedative administration, operative vs medical reason for admission, or the changing dynamics of sedation practice at different phases of critical illness. The lack of high-level evidence to inform sedation practice in the critically ill has led to approaches that are mainly opinion-based and lack the support of evidence from large multicentre, international randomised clinical trials.",[567],"Respiratory Insufficiency",[569,570,571,572],"Mechanical Ventilation","Sedation","Randomized Control Trial","Acute Respiratory Failure",{"date":546,"type":35},{"date":575,"type":23},"2025-09-07",{"date":577,"type":23},"2028-01-31",{"name":41,"class":42},{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":583,"acronym":584,"eligibilityCriteria":585,"healthyVolunteers":12,"sex":19,"minAge":50,"maxAge":4,"enrollmentInfo":586,"targetDuration":4,"studyType":54,"phases":588,"briefSummary":589,"conditions":590,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":597,"locationsCount":76},"100557598","the-development-safety-and-feasibility-of-an-artificial-intelligence-powered-platform-nodeai-for-real-time-prediction-of-mediastinal-lymph-node-malignancy-during-endobronchial-ultrasound-staging-for-lung-cancer-100557598","NCT06540196","The Development, Safety, and Feasibility of an Artificial Intelligence-Powered Platform (NodeAI) for Real-Time Prediction of Mediastinal Lymph Node Malignancy During Endobronchial Ultrasound Staging for Lung Cancer","NodeAI","Inclusion Criteria:\n\n* Patients ≥ 18 years of age diagnosed with suspected or confirmed NSCLC based on CT and PET scans that are referred for chest staging by EBUS-TBNA\n* CT and PET scans completed\n\nExclusion Criteria:\n\n* Patients with cN0 disease AND peripheral tumors AND tumors \\\u003C 2 cm in diameter (those do not require chest staging)",{"count":587,"type":23},600,[56],"Lung cancer is the leading cause of annual cancer deaths globally, more than breast, prostate, and colon cancers combined. The staging of chest lymph nodes (LNs) is a crucial step in the lung cancer diagnostic pathway because it aids in treatment decisions - whether a patient is a candidate for lung resection, chemotherapy, radiation, or multimodal treatments. Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA) is the current standard for chest nodal staging for non-small cell lung cancer (NSCLC), and guidelines mandate that Systematic Sampling (SS) of at least 3 chest LN stations be routinely performed for accurate staging. Unfortunately, EBUS-TBNA yields inaccurate results in 40% of patients, leading to misinformed treatment decisions. This proportion is much higher in patients with Triple Normal LNs \\[LNs that appear normal on computed tomography (CT) scans, positron emission tomography (PET) scans, and EBUS\\], which have been found to have a \\> 93% chance of being truly benign. This is because EBUS-TBNA is based on ultrasound, whose success highly depends on the skill of the person performing it (operator). When the operator makes an error, the entire procedure is jeopardized. This causes downstream delays in treatment due to repeated testing and ill-informed treatment decisions.\n\nOver the past decade, the investigator has been conducting a series of research studies and trials: the development and validation of the Canada Lymph Node Score (CLNS) - a surgeon-derived semi-quantitative measure of LN malignancy; an Artificial Intelligence (AI)-based version of the CLNS to predict malignancy; and a fully autonomous AI that learned to predict malignancy directly from ultrasound images, to introduce AI to the decision-making pathway in NSCLC. This resulted in the creation of an AI-powered software to predict malignancy in mediastinal LNs of patients with lung cancer. The software is currently housed in cloud storage and its applications are latent - which means that LN images must be uploaded to the software, and results are received at a future time. In its current form, the software is not ready for clinical application due to this latency. In this project, the investigator aims to build a point-of-care device which will house the software (NodeAI) and deliver real-time results to the surgeon, and this device will be tested in a clinical trial.",[191,299],"2025-06-11",{"date":593,"type":35},"2025-06-12",{"date":595,"type":35},"2025-01-10",{"date":361,"type":23},{"name":41,"class":42},{"id":599,"slug":600,"hasResults":12,"nctId":601,"briefTitle":602,"officialTitle":603,"acronym":4,"eligibilityCriteria":604,"healthyVolunteers":18,"sex":19,"minAge":605,"maxAge":606,"enrollmentInfo":607,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":609,"conditions":610,"keywords":612,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":620,"completionDateStruct":622,"leadSponsor":624,"locationsCount":76},"100515580","objective-concussion-assessment-using-mri-and-metabolomics-100515580","NCT05993351","Objective Concussion Assessment Using MRI and Metabolomics","Correlating Advanced MRI Techniques With Neuropsychological Analysis and Immunosensing Assays for Assessment of Sport-related Mild Traumatic Brain Injuries (mTBI)","Inclusion Criteria:\n\n* Aged between 9-50\n* Recently sustained a concussion (within the last 2 weeks)\n\nExclusion Criteria:\n\n* Aged 8 and younger or 51 and older\n* Unable to provide consent (e.g., poor English language skills, etc.)\n* History of liver or kidney disease\n* MRI contraindications:\n\n  * Pacemaker\n  * Stent\n  * Joint prothesis\n  * Implanted devices\n  * Claustrophobia\n  * Pregnant\n  * Permanent piercings\n* Chronic\u002Fabusive use of alcohol and\u002For illicit drugs\n* Previous stroke or moderate\u002Fsevere traumatic brain injury, subarachnoid hemorrhage, or intracranial hemorrhage\n* Healthy control participants must not have a concussion history or recently sustained a concussion","9 Years","50 Years",{"count":608,"type":23},100,"Mild traumatic brain injury (mTBI), also referred to as concussions, affect millions of people around the world and can cause harmful long term effects. Unfortunately, concussions can be hard to diagnose and many people have lasting post-concussion symptoms such as headaches, difficulty concentrating, and light sensitivity. Recent studies have shown that advanced magnetic resonance imaging (MRI) techniques can identify subtle brain changes caused by a concussion. This study aims to track concussions over time measuring MRI brain scans and post-concussion symptoms to gain a better understand how the brain is affected in comparison to symptoms.",[611],"Concussion, Brain",[613,614,615,616],"functional magnetic resonance imaging","diffusion tensor imaging","symptom tracking","sport-related concussions","2025-05-12",{"date":619,"type":35},"2025-05-15",{"date":621,"type":35},"2023-08-11",{"date":623,"type":23},"2026-12-15",{"name":41,"class":42},{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":630,"acronym":631,"eligibilityCriteria":632,"healthyVolunteers":12,"sex":139,"minAge":633,"maxAge":503,"enrollmentInfo":634,"targetDuration":4,"studyType":54,"phases":635,"briefSummary":636,"conditions":637,"keywords":642,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":650,"locationsCount":76},"100399217","phase-1-affect-of-duavive-on-mood--anxiety-symptoms-100399217","NCT04478305","Affect of Duavive on Mood & Anxiety Symptoms","The Effect of Conjugated Estrogens\u002F Bazedoxifene (CE\u002F BZA) on Peri- and Postmenopausal Mood and Anxiety Symptoms: A Pilot Study","DOMA","Inclusion Criteria:\n\n* Females between 45-60 years of age\n* Able to communicate in English\n* In perimenopause as defined by World Health Organization (WHO) Stages of Reproductive Aging Workshop (STRAW) criteria, OR in early menopause (within 10 years of final menstrual period)\n* Suffering from Depressive symptoms (10+ on CES-D-10) AND\u002FOR anxiety symptoms (10+ on GAD-7)\n\nExclusion Criteria:\n\n* Personal history of breast\u002F ovarian\u002F endometrial cancer\u002F endometrial hyperplasia.\n* Abnormal uterine bleeding that has not been adequately investigated.\n* Active or past venous or arterial thromboembolic disease (deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction, coronary heart disease).\n* Active liver disease.\n* Known protein C, protein S, or antithrombin deficiency or other known thrombophilic disorders.\n* Known or suspected pregnancy, women who may become pregnant, and nursing mothers\n* Partial or complete loss of vision due to ophthalmic vascular disease.\n* Uncontrolled hypertension (Systolic blood pressure \\>160mm Hg and\u002F or diastolic blood pressure \\>95 mm Hg)\n* Endocrine disease (other than thyroid disease) that may adversely affect mood (i.e., Cushing's disease, Addison's disease). For women with abnormal TSH, it will be corrected in advance of trial initiation.\n* Active serious suicidal ideation with intent.\n* Symptoms of active psychosis.\n* Daily use of antidepressive medication.\n* Use of other psychoactive or centrally acting medications within 2 weeks before study screening.\n* Known hypersensitivity to either CE or BZA.","45 Years",{"count":506,"type":23},[295],"This study evaluates the impact of conjugated estrogens\u002F bazedoxifene (CE\u002F BZA) on the mood (depression and anxiety) in peri- and early menopausal women.",[638,639,640,641],"Menopause","Depression, Anxiety","Sleep","Menopause Related Conditions",[643],"hormone replacement therapy","2024-11-28",{"date":646,"type":35},"2024-12-03",{"date":648,"type":35},"2024-07-03",{"date":492,"type":23},{"name":41,"class":42},{"id":652,"slug":653,"hasResults":12,"nctId":654,"briefTitle":655,"officialTitle":656,"acronym":4,"eligibilityCriteria":657,"healthyVolunteers":12,"sex":19,"minAge":50,"maxAge":4,"enrollmentInfo":658,"targetDuration":4,"studyType":54,"phases":660,"briefSummary":661,"conditions":662,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":664,"lastUpdatePostDateStruct":665,"startDateStruct":667,"completionDateStruct":669,"leadSponsor":671,"locationsCount":76},"100516099","duration-of-face-down-positioning-for-full-thickness-macular-hole-repair-100516099","NCT06000111","Duration of Face Down Positioning for Full-Thickness Macular Hole Repair","Duration of Face Down Positioning Following Full-Thickness Macular Hole Repair: a Randomized Feasibility Study","Inclusion Criteria:\n\n* Consecutive patients with an idiopathic full-thickness macular hole\n* Symptom duration of less than 6 months\n* Patient must agree to participate in this investigation\n\nExclusion Criteria:\n\n* Macular hole minimum diameter \\>1000 μm\n* A history of high myopia (\\> -6)\n* Traumatic macular hole\n* Amblyopia\n* Retinal vein occlusion\n* Inflammatory eye diseases\n* Patients found to have a retinal tear during either the pre-operative assessment or intraoperatively",{"count":659,"type":23},40,[56],"A full-thickness macular hole is when there is a small gap that opens in the center part of the retina (the light-sensitive layer of tissue in the back of the eye). Following surgical repair of these holes, patients have to lie face down for a number of days and nights. The exact amount of time necessary to position is however unknown. The goal of this randomized feasibility clinical trial is to compare 3 days and nights of face-down positioning to 7 days and nights of face-down positioning following pars plana vitrectomy surgery for full-thickness macular holes on key patient outcomes. This study will be a feasibility study to better inform a future larger clinical trial. Additionally, this investigation will be examining the rates of macular hole closure, patient visual acuity following surgery, patient quality of life, patient compliance, and complication rates.",[663],"Macular Holes","2024-11-26",{"date":666,"type":35},"2024-11-29",{"date":668,"type":35},"2023-11-21",{"date":670,"type":23},"2025-12-31",{"name":41,"class":42},""]